• Cat-intel
  • MedIntelliX
  • Resources
  • About Us
  • Hero Background
    English
    Chinese
    French
    Japanese
    Korean
    German
    Spanish

    Veterinary/Animal Vaccines Market Analysis

    ID: MRFR/Pharma/1994-CR
    133 Pages
    Kinjoll Dey
    May 2019

    Veterinary (Animal) Vaccines Market Research Report Information By Type (Livestock Vaccines, Porcine Vaccines), Technology (Live Attenuated Vaccines, Inactivated Vaccines), and Region (Americas, Europe, Asia-Pacific, and the Middle East & Africa) - Forecast till 2032

    Share:
    Download PDF ×

    We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

    Veterinary/Animal Vaccines Market Infographic
    $ 4,950.0
    $ 5,950.0
    $ 7,250.0

    Market Analysis

    In-depth Analysis of Veterinary/Animal Vaccines Market Industry Landscape

    A major factor affecting the market for hemiplegic migraines is the limited therapeutic choices available. HM is rare and intricate, making it difficult for pharmaceutical firms to develop tailored therapies. This creates industrial innovation possibilities. Diagnostic equipment and methodology developments are progressively supporting the sector's dynamics. Accurate and early identification of hemiplegic migraine improves patient outcomes and allows for more targeted therapy. Genetic study on hemiplegic migraine has increased. Scientists found genetic markers linked to HM, paving the way for precision medication targeted to people with unique hereditary predispositions. Recent neurology and neuroscience findings affect market dynamics. As we learn more about the brain mechanisms that cause hemiplegic migraine, we may develop tailored medicines that target those pathways. Clinical studies for hemiplegic migraine are difficult due to their rarity. Both enrolling enough people and generating statistically meaningful data may be problematic, slowing the development of prospective drugs. One regulatory classification that might affect market dynamics is orphan medication status. Businesses researching hemiplegic head pain treatments may pursue orphan drug classification. This categorization financially rewards research and development to meet the medical requirements of a certain patient group. Telemedicine is changing how hemiplegic migraine sufferers get treatment. Telemedicine allows remote consultations and follow-ups. This increases the availability of expert medical professionals and may improve the treatment experience for HM patients. Patient-centered approaches to hemiplegic migraine are growing in favor. A rising number of healthcare companies and professionals recognize the importance of patient involvement in therapy development and research. This ensures that solutions are tailored to HM patients' requirements. Pharmaceutical corporations, research institutes, and patient advocacy organizations must work to solve hemiplegic migraine issues. Creating global alliances that stimulate resource and information exchange may speed up the research and treatment of this rare disease. This may be done by accelerating development.

    Author
    Kinjoll Dey
    Research Analyst Level I

    He is an extremely curious individual currently working in Healthcare and Medical Devices Domain. Kinjoll is comfortably versed in data centric research backed by healthcare educational background. He leverages extensive data mining and analytics tools such as Primary and Secondary Research, Statistical Analysis, Machine Learning, Data Modelling. His key role also involves Technical Sales Support, Client Interaction and Project management within the Healthcare team. Lastly, he showcases extensive affinity towards learning new skills and remain fascinated in implementing them.

    Leave a Comment

    FAQs

    Which regions will have the highest CAGR in veterinary/animal vaccines market?

    North America and Asia-Pacific

    What are the recent trends in the veterinary/animal vaccines market?

    More technological advancement is leading to better and more innovative vaccines

    Who are the key competitors in the veterinary/animal vaccines market?

    Zoetis (US), Virbac SA (France), Merck (US), Phibro Animal Health Corporation (US), Boehringer Ingelheim (Germany), Ceva (France), Elanco (US)

    Market Summary

    The Global Veterinary Vaccines Market is projected to grow from 6.27 USD Billion in 2024 to 15.4 USD Billion by 2032.

    Key Market Trends & Highlights

    Veterinary (Animal) Vaccines Key Trends and Highlights

    • The market is expected to experience a compound annual growth rate of 8.48 percent from 2024 to 2032. By 2032, the market valuation is anticipated to reach 15.4 USD Billion, indicating robust growth potential. In 2024, the market is valued at 6.27 USD Billion, reflecting a strong foundation for future expansion. Growing adoption of advanced vaccination technologies due to increasing awareness of animal health is a major market driver.

    Market Size & Forecast

    2024 Market Size 6.27 (USD Billion)
    2032 Market Size 15.4 (USD Billion)
    CAGR (2024-2032) 8.48%
    Largest Regional Market Share in 2024 latin_america)

    Major Players

    <p>Zoetis, Virbac SA, Merck, Phibro Animal Health Corporation, Boehringer Ingelheim, Ceva, Elanco</p>

    Market Trends

    Drivers

    As the middle classes around the world explode, so does the preference to keep pets. Most people keep cats and dogs as pets.. These pets need vaccines in order to stay healthy. This is one large driver of growth in the veterinary/animal vaccines market. 

    Growing middle classes around the world means that the demand for meat consumption is rising dramatically around the world. This raises the importance of veterinary vaccines because farm animals need to be vaccinated before they are slaughtered for human consumption. 

    This keeps the meat healthier and helps it last longer. It also keeps animals from developing dangerous bacteria, parasites, and viruses that can harm or even kill humans. In fact, according to the international veterinary vaccines and diagnostics conference 2006 the demand for various types of animal vaccines will increase dramatically in later years. 

    Opportunities

    There are many emerging opportunities in the veterinary/animal vaccines market. Many veterinary clinics are investing heavily in research and development to develop and market more advanced vaccines that will keep animals healthier and stronger and help them live longer. 

    Vaccines for animals are also getting a strong boost from technological advancements. It’s advancements in technology that promise to make a new generation of stronger animal vaccines that are much more effective and last longer. 

    Research and development will also allow vaccine manufacturers to develop and market hybrid vaccines. These will be much more effective, hence they will be extremely profitable. 

    Restraints

    All vaccines have side effects. Animal vaccines are no exception. This is a key restraint in the veterinary/animal vaccines market. Most farmers and pet owners are loath to get their animals vaccinated because they are all too aware of the side effects but they are not aware enough of the benefits of these vaccines. Most farmers don’t get their animals vaccinated for this reason. This is the case in developing nations. 

    The animal vaccine market is also heavily regulated. This is another factor that’s holding back growth in the Veterinary (Animal) Vaccines Market. 

    Challenges

    Some animal vaccines for some segments of animals are very expensive. This factor is a major challenge in the veterinary/animal vaccines market. Animal vaccine manufacturers will also have to find ways to better educate animal owners about the benefits of animal vaccines. 

    Technology analysis

    Merck is a major American player in the Veterinary (Animal) Vaccines Market. It became an industry leader by creating a sustainable competitive advantage. Intensive investments in research and development have allowed it to do this. In the field of animal research, the value of vaccines has been established significantly. 

    Animals and pets have both been immunized for many years. In the near future, beekeepers might be able to immunize their colonies. As of October 2022, the first honeybee vaccine in the world is being developed by the University of Georgia College of Agricultural and Environmental Sciences (CAES) and Dalan Animal Health.

    <p>The ongoing advancements in veterinary vaccine development are poised to enhance animal health outcomes and may contribute to the overall sustainability of livestock production systems.</p>

    U.S. Department of Agriculture (USDA)

    Veterinary/Animal Vaccines Market Market Drivers

    Rising Pet Ownership

    The increasing trend of pet ownership globally is a primary driver for the Global Veterinary Animal Vaccines Market Industry. As more households adopt pets, the demand for veterinary services, including vaccinations, rises significantly. In 2024, the market is valued at 6.27 USD Billion, reflecting the growing concern among pet owners for their animals' health. This trend is particularly pronounced in urban areas, where pet ownership rates have surged. Consequently, the need for effective vaccines to prevent diseases in pets is becoming more critical, thereby propelling the market forward.

    Market Growth Projections

    The Global Veterinary Animal Vaccines Market Industry is projected to experience substantial growth in the coming years. With a market value of 6.27 USD Billion in 2024, it is anticipated to reach 15.4 USD Billion by 2035. This growth trajectory indicates a compound annual growth rate of 8.48% from 2025 to 2035. Such projections reflect the increasing demand for veterinary vaccines driven by factors such as rising pet ownership, advancements in vaccine technology, and heightened awareness of animal health. The market's expansion is indicative of the critical role that vaccines play in ensuring the health and well-being of animals globally.

    Emerging Zoonotic Diseases

    The emergence of zoonotic diseases is a significant driver for the Global Veterinary Animal Vaccines Market Industry. As new diseases that can be transmitted from animals to humans arise, there is an urgent need for effective vaccination strategies to control outbreaks. This concern is particularly relevant in regions where livestock and wildlife interactions are frequent. The increasing incidence of such diseases highlights the necessity for robust vaccination programs, thereby propelling market growth. The focus on preventing zoonotic diseases is expected to contribute to the overall expansion of the market in the coming years.

    Regulatory Support and Standards

    Regulatory frameworks and standards established by government agencies play a crucial role in shaping the Global Veterinary Animal Vaccines Market Industry. Governments worldwide are implementing stringent regulations to ensure the safety and efficacy of veterinary vaccines. This regulatory support fosters consumer confidence and encourages veterinarians to adopt new vaccines. Moreover, compliance with these regulations often leads to improved product quality, which can enhance market growth. As the industry evolves, adherence to these standards will likely remain a key driver for the market, ensuring that animal health is prioritized.

    Advancements in Vaccine Technology

    Technological advancements in vaccine development are transforming the Global Veterinary Animal Vaccines Market Industry. Innovations such as recombinant vaccines and mRNA technology are enhancing vaccine efficacy and safety. These advancements not only improve the immune response in animals but also reduce the incidence of adverse effects. As a result, veterinarians are more likely to recommend these modern vaccines, further driving market growth. The anticipated market expansion to 15.4 USD Billion by 2035 underscores the importance of these technological developments in meeting the evolving needs of animal health.

    Increased Awareness of Animal Health

    There is a growing awareness among pet owners and livestock producers regarding the importance of animal health, which significantly influences the Global Veterinary Animal Vaccines Market Industry. Educational campaigns and outreach programs by veterinary associations have heightened understanding of the benefits of vaccinations. This awareness leads to increased vaccination rates, thereby reducing the prevalence of infectious diseases in animals. As the market continues to expand, the projected compound annual growth rate of 8.48% from 2025 to 2035 indicates that this trend will likely persist, further solidifying the role of vaccines in animal health.

    Market Segment Insights

    Veterinary/Animal Vaccines Type Insights

    <p>The&nbsp;veterinary/animal vaccines&nbsp;market can be grouped into the following sub-segments by type:</p>

    <p>The attenuated vaccines sub-segment held the highest market share last year because they do a better job of boosting animals’ immune systems than other vaccines do. Also, animals who get attenuated vaccines need fewer booster shots less often. Most booster vaccines are given to animals orally.&nbsp;</p>

    <p>This makes them less effective in strengthening the animals’ immune systems and keeping them healthier than vaccines that are given by injection.&nbsp;</p>

    Veterinary/Animal Vaccines Disease Insights

    <p>The&nbsp;Veterinary (Animal) Vaccines Market can be grouped into the following sub-segments by disease:</p>

    Veterinary/Animal Vaccines Technology Insights

    <p>The&nbsp;Veterinary (Animal) Vaccines Market can be grouped into the following sub-segments by type:</p>

    <p>By Type (Livestock)</p>

    <p>The Department of Animal Husbandry and Dairying (DAHD) advised states to immunize cattle and buffaloes with the available Goat pox vaccine on September 20, 2021, despite the fact that lumpy skin disease has already killed almost 1 lakh cattle and infected over 20 lakh animals across 15 states. The only manufacturer of the goatpox vaccine in the nation at the time of authorization was Hester Biosciences in Gujarat; IIL, the Hyderabad-based Brilliant Bio Pharma Pvt Ltd, introduced its goatpox vaccine in December 2021.</p>

    Get more detailed insights about Veterinary (Animal) Vaccines Market Research Report - Forecast till 2032

    Regional Insights

    Key Companies in the Veterinary/Animal Vaccines Market market include

    Industry Developments

    • Many key companies in the Veterinary (Animal) Vaccines Market have stayed successful by entering into strategic partnerships with other successful companies. They have managed to develop a new vaccine for poultry (chicks to be exact). This is very effective so it has great revenue generation potential.
    • Big companies are partnering up to develop new aquaculture vaccines that will do a better job of protecting aquatic life from diseases.
    • Elanco acquired a new animal vaccine company as part of its expansion strategy

     

    Future Outlook

    Veterinary/Animal Vaccines Market Future Outlook

    <p>The Veterinary (Animal) Vaccines Market is projected to grow at an 8.48% CAGR from 2024 to 2032, driven by increasing pet ownership, advancements in vaccine technology, and rising awareness of animal health.</p>

    New opportunities lie in:

    • <p>Develop personalized vaccines targeting specific animal breeds. Leverage digital platforms for vaccine distribution and education. Invest in R&amp;D for innovative adjuvants to enhance vaccine efficacy.</p>

    <p>By 2035, the Veterinary (Animal) Vaccines Market is expected to achieve substantial growth, reflecting evolving industry dynamics.</p>

    Market Segmentation

    Report Scope

    Attribute/MetricDetails
      Market Size 2032  11.8 (USD) Billion
      CAGR  9.2% (2023-2032)
      Base Year2023
      Forecast Period  2023-2032
      Historical Data  2020
      Forecast Units  Value (USD Billion)
      Report Coverage  Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
      Segments Covered  Type, Technology, Region
      Geographies Covered  North America, Europe, Asia-Pacific, Rest of the World
      Key Vendors  Zoetis (US), Virbac SA (France), Merck (US), Phibro Animal Health Corporation (US), Boehringer Ingelheim (Germany), Ceva (France), Elanco (US)
      Key Market Opportunities·  High development opportunities in the upcoming years ·  Technological developments
      Key Market Drivers·  The increasing rate of pet adoption ·  Rising expenditure on the pet treatment ·  High consumption of meat

    Market Highlights

    Author

    Kinjoll Dey
    Research Analyst Level I

    She holds an experience of about 6+ years in market research and business consulting, working under the spectrum of information communication technology, telecommunications and semiconductor domains. aarti conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. her expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc.

    Leave a Comment

    Latest Comments

    John Doe
    john@example.com

    This is a great article! Really helped me understand the topic better.

    Posted on July 23, 2025, 10:15 AM
    Jane Smith
    jane@domain.com

    Thanks for sharing this. I’ve bookmarked it for later reference.

    Posted on July 22, 2025, 7:45 PM

    FAQs

    Which regions will have the highest CAGR in veterinary/animal vaccines market?

    North America and Asia-Pacific

    What are the recent trends in the veterinary/animal vaccines market?

    More technological advancement is leading to better and more innovative vaccines

    Who are the key competitors in the veterinary/animal vaccines market?

    Zoetis (US), Virbac SA (France), Merck (US), Phibro Animal Health Corporation (US), Boehringer Ingelheim (Germany), Ceva (France), Elanco (US)

    1. Report Prologue
    2. Executive Summary
    3. Market Introduction
      1. Definition 18
      2. Scope of the Study 18
      3. Research Objective 18
      4. Assumptions & Limitations 18
        1. Assumptions 18
        2. Limitations 18
      5. Market Structure 19
    4. Research Methodology
      1. Research Process 21
      2. Primary Research 22
      3. Secondary Research 23
      4. Market Size Estimation 24
      5. Forecast Model 24
    5. Market Dynamics
      1. Introduction 26
      2. Drivers 27
        1. Increasing Number of Pet Owners 27
        2. Growing Livestock Population and Disease Outbreaks 27
        3. Advances in Technology underlying Veterinary Vaccines 27
        4. Various Initiatives by Several Government Agencies, Animal Associations, and Prominent Market Players 28
      3. Restraint 28
        1. High Storage Cost associated with Veterinary Vaccines 28
      4. Opportunity 28
        1. Rising Investments to Improve Animal Health 28
    6. Market Factor Analysis
      1. Porter’s Five Forces Model 30
        1. Bargaining Power of Suppliers 30
        2. Bargaining Power of Buyers 31
        3. Threat of New Entrants 31
        4. Threat of Substitutes 31
        5. Rivalry 31
      2. Supply Chain Analysis 31
        1. R&D and Development 32
        2. Manufacturing 32
        3. Distribution & Sales 32
        4. Post-Sales Monitoring 32
    7. Veterinary (Animal) Vaccines Market, by Type
      1. Introduction 35
        1. Livestock Vaccines 37
        2. Porcine Vaccines 38
        3. Companion Animal Vaccines 38
        4. Poultry Vaccines 39
        5. Aquaculture Vaccines 39
    8. Veterinary (Animal) Vaccines Market, by Technology
      1. Introduction 41
        1. Live Attenuated Vaccines 43
        2. Inactivated Vaccines 43
        3. Recombinant Vaccines 44
        4. Toxoid Vaccines 44
    9. Global Veterinary (Animal) Vaccines Market, by Region
      1. Introduction 46
      2. Americas 48
    10. Veterinary (Animal) Vaccines Market, by Type
    11. Veterinary (Animal) Vaccines Market, by Technology
    12. North America 51
    13. Veterinary (Animal) Vaccines Market, by Type
    14. Veterinary (Animal) Vaccines Market, by Technology
    15. US 53
    16. Veterinary (Animal) Vaccines Market, by Type
    17. Veterinary (Animal) Vaccines Market, by Technology
    18. Canada 55
    19. Veterinary (Animal) Vaccines Market, by Type
    20. Veterinary (Animal) Vaccines Market, by Technology
    21. South America 57
    22. Veterinary (Animal) Vaccines Market, by Type
    23. Veterinary (Animal) Vaccines Market, by Technology
      1. Europe 60
    24. Veterinary (Animal) Vaccines Market, by Type
    25. Veterinary (Animal) Vaccines Market, by Technology
    26. Western Europe 63
    27. Veterinary (Animal) Vaccines Market, by Type
    28. Veterinary (Animal) Vaccines Market, by Technology
    29. France 65
    30. Veterinary (Animal) Vaccines Market, by Type
    31. Veterinary (Animal) Vaccines Market, by Technology
    32. Germany 67
    33. Veterinary (Animal) Vaccines Market, by Type
    34. Veterinary (Animal) Vaccines Market, by Technology
    35. UK 69
    36. Veterinary (Animal) Vaccines Market, by Type
    37. Veterinary (Animal) Vaccines Market, by Technology
    38. Spain 71
    39. Veterinary (Animal) Vaccines Market, by Type
    40. Veterinary (Animal) Vaccines Market, by Technology
    41. Italy 73
    42. Veterinary (Animal) Vaccines Market, by Type
    43. Veterinary (Animal) Vaccines Market, by Technology
    44. Rest of Western Europe 75
    45. Veterinary (Animal) Vaccines Market, by Type
    46. Veterinary (Animal) Vaccines Market, by Technology
    47. Eastern Europe 77
    48. Veterinary (Animal) Vaccines Market, by Type
    49. Veterinary (Animal) Vaccines Market, by Technology
      1. Asia-Pacific 80
    50. Veterinary (Animal) Vaccines Market, by Type
    51. Veterinary (Animal) Vaccines Market, by Technology
    52. Japan 83
    53. Veterinary (Animal) Vaccines Market, by Type
    54. Veterinary (Animal) Vaccines Market, by Technology
    55. China 85
    56. Veterinary (Animal) Vaccines Market, by Type
    57. Veterinary (Animal) Vaccines Market, by Technology
    58. India 87
    59. Veterinary (Animal) Vaccines Market, by Type
    60. Veterinary (Animal) Vaccines Market, by Technology
    61. Australia 89
    62. Veterinary (Animal) Vaccines Market, by Type
    63. Veterinary (Animal) Vaccines Market, by Technology
    64. Republic of Korea 91
    65. Veterinary (Animal) Vaccines Market, by Type
    66. Veterinary (Animal) Vaccines Market, by Technology
    67. Rest of Asia-Pacific 93
    68. Veterinary (Animal) Vaccines Market, by Type
    69. Veterinary (Animal) Vaccines Market, by Technology
      1. Middle East and Africa 95
    70. Veterinary (Animal) Vaccines Market, by Type
    71. Veterinary (Animal) Vaccines Market, by Technology
    72. Middle East 98
    73. Veterinary (Animal) Vaccines Market, by Type
    74. Veterinary (Animal) Vaccines Market, by Technology
    75. Africa 100
    76. Veterinary (Animal) Vaccines Market, by Type
    77. Veterinary (Animal) Vaccines Market, by Technology
    78. Competitive Landscape
      1. Introduction 103
    79. Company Profiles
      1. Boehringer Ingelheim International GmbH 106
        1. Company Overview 106
        2. Financial Overview 106
        3. Products/Services Offered 107
        4. Key Developments 107
        5. SWOT Analysis 107
        6. Key Strategies 107
      2. Zoetis 108
        1. Company Overview 108
        2. Financial Overview 108
        3. Products/Services Offered 109
        4. Key Developments 109
        5. SWOT Analysis 110
        6. Key Strategies 110
      3. Ceva 111
        1. Company Overview 111
        2. Financial Overview 111
        3. Products/Services Offered 112
        4. Key Developments 112
        5. SWOT Analysis 113
        6. Key Strategies 113
      4. MSD & Co. Inc. 114
        1. Company Overview 114
        2. Financial Overview 114
        3. Products/Services Offered 115
        4. Key Developments 116
        5. SWOT Analysis 116
        6. Key Strategies 116
      5. Elanco 117
        1. Company Overview 117
        2. Financial Overview 117
        3. Products/Services Offered 118
        4. Key Developments 118
        5. SWOT Analysis 118
        6. Key Strategies 119
      6. Virbac 120
        1. Company Overview 120
        2. Financial Overview 120
        3. Products/Services Offered 121
        4. Key Developments 121
        5. SWOT Analysis 121
        6. Key Strategies 121
      7. Phibro Animal Health Corporation. 122
        1. Company Overview 122
        2. Financial Overview 122
        3. Products/Services Offered 123
        4. Key Developments 123
        5. SWOT Analysis 123
        6. Key Strategies 123
      8. Hipra 124
        1. Company Overview 124
        2. Financial Overview 124
        3. Products/Services Offered 124
        4. Key Developments 125
        5. SWOT Analysis 125
        6. Key Strategies 125
      9. IDT Biologika GmbH 126
        1. Company Overview 126
        2. Financial Overview 126
        3. Products/Services Offered 126
        4. Key Developments 126
        5. SWOT Analysis 127
        6. Key Strategies 127
      10. Biogenesis Bago SA 128
        1. Company Overview 128
        2. Financial Overview 128
        3. Products/Services Offered 128
        4. Key Developments 128
        5. SWOT Analysis 129
        6. Key Strategies 129
    80. Appendix
      1. Discussion Blue Print 131
    81. List of Tables
    82. MARKET SYNOPSIS 16
    83. PRIMARY INTERVIEWS 21
    84. GLOBAL Veterinary (Animal) Vaccines Market, BY TYPE, 2020–2027 (USD MILLION) 36
    85. GLOBAL Veterinary (Animal) Vaccines Market, FOR LIVESTOCK VACCINES, BY TYPE, 2020–2027 (USD MILLION) 36
    86. GLOBAL Veterinary (Animal) Vaccines Market, FOR COMPANION ANIMAL VACCINES, BY TYPE, 2020–2027 (USD MILLION) 37
    87. GLOBAL Veterinary (Animal) Vaccines Market, FOR LIVESTOCK VACCINES, BY REGION, 2020–2027 (USD MILLION) 37
    88. GLOBAL Veterinary (Animal) Vaccines Market, FOR PORCINE VACCINES, BY REGION, 2020–2027 (USD MILLION) 38
    89. GLOBAL Veterinary (Animal) Vaccines Market, FOR COMPANION ANIMAL VACCINES, BY REGION, 2020–2027
      1. (USD MILLION) 38
    90. GLOBAL Veterinary (Animal) Vaccines Market, FOR POULTRY VACCINES, BY REGION, 2020–2027 (USD MILLION) 39
    91. GLOBAL Veterinary (Animal) Vaccines Market, FOR AQUACULTURE VACCINES, BY REGION, 2020–2027 (USD MILLION) 39
    92. GLOBAL Veterinary (Animal) Vaccines Market, BY TECHNOLOGY, 2020–2027 (USD MILLION) 42
    93. GLOBAL Veterinary (Animal) Vaccines Market, FOR LIVE ATTENUATED VACCINES, BY REGION, 2020–2027 (USD MILLION) 43
    94. GLOBAL Veterinary (Animal) Vaccines Market, FOR INACTIVATED VACCINES, BY REGION, 2020–2027 (USD MILLION) 43
    95. GLOBAL Veterinary (Animal) Vaccines Market, FOR RECOMBINANT VACCINES, BY REGION, 2020–2027 (USD MILLION) 44
    96. GLOBAL Veterinary (Animal) Vaccines Market, FOR TOXOID VACCINES, BY REGION, 2020–2027 (USD MILLION) 44
    97. GLOBAL Veterinary (Animal) Vaccines Market, BY REGION, 2020–2027 (USD MILLION) 47
    98. AMERICAS: Veterinary (Animal) Vaccines Market, BY REGION, 2020–2027 (USD MILLION) 48
    99. AMERICAS: Veterinary (Animal) Vaccines Market, BY TYPE, 2020–2027 (USD MILLION) 49
    100. AMERICAS: Veterinary (Animal) Vaccines Market, FOR LIVESTOCK VACCINES, BY TYPE, 2020–2027 (USD MILLION) 49
    101. AMERICAS: Veterinary (Animal) Vaccines Market, FOR COMPANION ANIMAL VACCINES, BY TYPE, 2020–2027
      1. (USD MILLION) 50
    102. AMERICAS: Veterinary (Animal) Vaccines Market, BY TECHNOLOGY, 2020–2027 (USD MILLION) 50
    103. NORTH AMERICA: Veterinary (Animal) Vaccines Market, BY COUNTRY, 2020–2027 (USD MILLION) 51
    104. NORTH AMERICA: Veterinary (Animal) Vaccines Market, BY TYPE, 2020–2027 (USD MILLION) 51
    105. NORTH AMERICA: Veterinary (Animal) Vaccines Market, FOR LIVESTOCK VACCINES, BY TYPE, 2020–2027 (USD MILLION) 52
    106. NORTH AMERICA: Veterinary (Animal) Vaccines Market, FOR COMPANION ANIMAL VACCINES, BY TYPE, 2020–2027
      1. (USD MILLION) 52
    107. NORTH AMERICA: Veterinary (Animal) Vaccines Market, BY TECHNOLOGY, 2020–2027 (USD MILLION) 53
    108. US: Veterinary (Animal) Vaccines Market, BY TYPE, 2020–2027 (USD MILLION) 53
    109. US: Veterinary (Animal) Vaccines Market, FOR LIVESTOCK VACCINES, BY TYPE, 2020–2027 (USD MILLION) 54
    110. US: Veterinary (Animal) Vaccines Market, FOR COMPANION ANIMAL VACCINES, BY TYPE, 2020–2027 (USD MILLION) 54
    111. US: Veterinary (Animal) Vaccines Market, BY TECHNOLOGY, 2020–2027 (USD MILLION) 55
    112. CANADA: Veterinary (Animal) Vaccines Market, BY TYPE, 2020–2027 (USD MILLION) 55
    113. CANADA: Veterinary (Animal) Vaccines Market, FOR LIVESTOCK VACCINES, BY TYPE, 2020–2027 (USD MILLION) 56
    114. CANADA: Veterinary (Animal) Vaccines Market, FOR COMPANION ANIMAL VACCINES, BY TYPE, 2020–2027 (USD MILLION) 56
    115. CANADA: Veterinary (Animal) Vaccines Market, BY TECHNOLOGY, 2020–2027 (USD MILLION) 57
    116. SOUTH AMERICA: Veterinary (Animal) Vaccines Market, BY TYPE, 2020–2027 (USD MILLION) 57
    117. SOUTH AMERICA: Veterinary (Animal) Vaccines Market, FOR LIVESTOCK VACCINES, BY TYPE, 2020–2027 (USD MILLION) 58
    118. SOUTH AMERICA: Veterinary (Animal) Vaccines Market, FOR COMPANION ANIMAL VACCINES, BY TYPE, 2020–2027
      1. (USD MILLION) 58
    119. SOUTH AMERICA: Veterinary (Animal) Vaccines Market, BY TECHNOLOGY, 2020–2027 (USD MILLION) 59
    120. EUROPE: Veterinary (Animal) Vaccines Market, BY REGION, 2020–2027 (USD MILLION) 60
    121. EUROPE: Veterinary (Animal) Vaccines Market, BY TYPE, 2020–2027 (USD MILLION) 61
    122. EUROPE: Veterinary (Animal) Vaccines Market, FOR LIVESTOCK VACCINES, BY TYPE, 2020–2027 (USD MILLION) 61
    123. EUROPE: Veterinary (Animal) Vaccines Market, FOR COMPANION ANIMAL VACCINES, BY TYPE, 2020–2027 (USD MILLION) 62
    124. EUROPE: Veterinary (Animal) Vaccines Market, BY TECHNOLOGY, 2020–2027 (USD MILLION) 62
    125. WESTERN EUROPE: Veterinary (Animal) Vaccines Market, BY COUNTRY, 2020–2027 (USD MILLION) 63
    126. WESTERN EUROPE: Veterinary (Animal) Vaccines Market, BY TYPE, 2020–2027 (USD MILLION) 63
    127. WESTERN EUROPE: Veterinary (Animal) Vaccines Market, FOR LIVESTOCK VACCINES, BY TYPE, 2020–2027 (USD MILLION) 64
    128. WESTERN EUROPE: Veterinary (Animal) Vaccines Market, FOR COMPANION ANIMAL VACCINES, BY TYPE, 2020–2027
      1. (USD MILLION) 64
    129. WESTERN EUROPE: Veterinary (Animal) Vaccines Market, BY TECHNOLOGY, 2020–2027 (USD MILLION) 65
    130. FRANCE: Veterinary (Animal) Vaccines Market, BY TYPE, 2020–2027 (USD MILLION) 65
    131. FRANCE: Veterinary (Animal) Vaccines Market, FOR LIVESTOCK VACCINES, BY TYPE, 2020–2027 (USD MILLION) 66
    132. FRANCE: Veterinary (Animal) Vaccines Market, FOR COMPANION ANIMAL VACCINES, BY TYPE, 2020–2027 (USD MILLION) 66
    133. FRANCE: Veterinary (Animal) Vaccines Market, BY TECHNOLOGY, 2020–2027 (USD MILLION) 67
    134. GERMANY: Veterinary (Animal) Vaccines Market, BY TYPE, 2020–2027 (USD MILLION) 67
    135. GERMANY: Veterinary (Animal) Vaccines Market, FOR LIVESTOCK VACCINES, BY TYPE, 2020–2027 (USD MILLION) 68
    136. GERMANY: Veterinary (Animal) Vaccines Market, FOR COMPANION ANIMAL VACCINES, BY TYPE, 2020–2027
      1. (USD MILLION) 68
    137. GERMANY: Veterinary (Animal) Vaccines Market, BY TECHNOLOGY, 2020–2027 (USD MILLION) 69
    138. UK: Veterinary (Animal) Vaccines Market, BY TYPE, 2020–2027 (USD MILLION) 69
    139. UK: Veterinary (Animal) Vaccines Market, FOR LIVESTOCK VACCINES, BY TYPE, 2020–2027 (USD MILLION) 70
    140. UK: Veterinary (Animal) Vaccines Market, FOR COMPANION ANIMAL VACCINES, BY TYPE, 2020–2027 (USD MILLION) 70
    141. UK: Veterinary (Animal) Vaccines Market, BY TECHNOLOGY, 2020–2027 (USD MILLION) 71
    142. SPAIN: Veterinary (Animal) Vaccines Market, BY TYPE, 2020–2027 (USD MILLION) 71
    143. SPAIN: Veterinary (Animal) Vaccines Market, FOR LIVESTOCK VACCINES, BY TYPE, 2020–2027 (USD MILLION) 72
    144. SPAIN: Veterinary (Animal) Vaccines Market, FOR COMPANION ANIMAL VACCINES, BY TYPE, 2020–2027 (USD MILLION) 72
    145. SPAIN: Veterinary (Animal) Vaccines Market, BY TECHNOLOGY, 2020–2027 (USD MILLION) 73
    146. ITALY: Veterinary (Animal) Vaccines Market, BY TYPE, 2020–2027 (USD MILLION) 73
    147. ITALY: Veterinary (Animal) Vaccines Market, FOR LIVESTOCK VACCINES, BY TYPE, 2020–2027 (USD MILLION) 74
    148. ITALY: Veterinary (Animal) Vaccines Market, FOR COMPANION ANIMAL VACCINES, BY TYPE, 2020–2027 (USD MILLION) 74
    149. ITALY: Veterinary (Animal) Vaccines Market, BY TECHNOLOGY, 2020–2027 (USD MILLION) 75
    150. REST OF WESTERN EUROPE: Veterinary (Animal) Vaccines Market, BY TYPE, 2020–2027 (USD MILLION) 75
    151. REST OF WESTERN EUROPE: Veterinary (Animal) Vaccines Market, FOR LIVESTOCK VACCINES, BY TYPE, 2020–2027
      1. (USD MILLION) 76
    152. REST OF WESTERN EUROPE: Veterinary (Animal) Vaccines Market, FOR COMPANION ANIMAL VACCINES, BY TYPE, 2020–2027 (USD MILLION) 76
    153. REST OF WESTERN EUROPE: Veterinary (Animal) Vaccines Market, BY TECHNOLOGY, 2020–2027 (USD MILLION) 77
    154. EASTERN EUROPE: Veterinary (Animal) Vaccines Market, BY TYPE, 2020–2027 (USD MILLION) 77
    155. EASTERN EUROPE: Veterinary (Animal) Vaccines Market, FOR LIVESTOCK VACCINES, BY TYPE, 2020–2027 (USD MILLION) 78
    156. EASTERN EUROPE: Veterinary (Animal) Vaccines Market, FOR COMPANION ANIMAL VACCINES, BY TYPE, 2020–2027
      1. (USD MILLION) 78
    157. EASTERN EUROPE: Veterinary (Animal) Vaccines Market, BY TECHNOLOGY, 2020–2027 (USD MILLION) 79
    158. ASIA-PACIFIC: Veterinary (Animal) Vaccines Market, BY COUNTRY, 2020–2027 (USD MILLION) 80
    159. ASIA-PACIFIC: Veterinary (Animal) Vaccines Market, BY TYPE, 2020–2027 (USD MILLION) 81
    160. ASIA-PACIFIC: Veterinary (Animal) Vaccines Market, FOR LIVESTOCK VACCINES, BY TYPE, 2020–2027 (USD MILLION) 81
    161. ASIA-PACIFIC: Veterinary (Animal) Vaccines Market, FOR COMPANION ANIMAL VACCINES, BY TYPE, 2020–2027
      1. (USD MILLION) 82
    162. ASIA-PACIFIC: Veterinary (Animal) Vaccines Market, BY TECHNOLOGY, 2020–2027 (USD MILLION) 82
    163. JAPAN: Veterinary (Animal) Vaccines Market, BY TYPE, 2020–2027 (USD MILLION) 83
    164. JAPAN: Veterinary (Animal) Vaccines Market, FOR LIVESTOCK VACCINES, BY TYPE, 2020–2027 (USD MILLION) 83
    165. JAPAN: Veterinary (Animal) Vaccines Market, FOR COMPANION ANIMAL VACCINES, BY TYPE, 2020–2027 (USD MILLION) 84
    166. JAPAN: Veterinary (Animal) Vaccines Market, BY TECHNOLOGY, 2020–2027 (USD MILLION) 84
    167. CHINA: Veterinary (Animal) Vaccines Market, BY TYPE, 2020–2027 (USD MILLION) 85
    168. CHINA: Veterinary (Animal) Vaccines Market, FOR LIVESTOCK VACCINES, BY TYPE, 2020–2027 (USD MILLION) 85
    169. CHINA: Veterinary (Animal) Vaccines Market, FOR COMPANION ANIMAL VACCINES, BY TYPE, 2020–2027 (USD MILLION) 86
    170. CHINA: Veterinary (Animal) Vaccines Market, BY TECHNOLOGY, 2020–2027 (USD MILLION) 86
    171. INDIA: Veterinary (Animal) Vaccines Market, BY TYPE, 2020–2027 (USD MILLION) 87
    172. INDIA: Veterinary (Animal) Vaccines Market, FOR LIVESTOCK VACCINES, BY TYPE, 2020–2027 (USD MILLION) 87
    173. INDIA: Veterinary (Animal) Vaccines Market, FOR COMPANION ANIMAL VACCINES, BY TYPE, 2020–2027 (USD MILLION) 88
    174. INDIA: Veterinary (Animal) Vaccines Market, BY TECHNOLOGY, 2020–2027 (USD MILLION) 88
    175. AUSTRALIA: Veterinary (Animal) Vaccines Market, BY TYPE, 2020–2027 (USD MILLION) 89
    176. AUSTRALIA: Veterinary (Animal) Vaccines Market, FOR LIVESTOCK VACCINES, BY TYPE, 2020–2027 (USD MILLION) 89
    177. AUSTRALIA: Veterinary (Animal) Vaccines Market, FOR COMPANION ANIMAL VACCINES, BY TYPE, 2020–2027
      1. (USD MILLION) 90
    178. AUSTRALIA: Veterinary (Animal) Vaccines Market, BY TECHNOLOGY, 2020–2027 (USD MILLION) 90
    179. REPUBLIC OF KOREA: Veterinary (Animal) Vaccines Market, BY TYPE, 2020–2027 (USD MILLION) 91
    180. REPUBLIC OF KOREA: Veterinary (Animal) Vaccines Market, FOR LIVESTOCK VACCINES, BY TYPE, 2020–2027
      1. (USD MILLION) 91
    181. REPUBLIC OF KOREA: Veterinary (Animal) Vaccines Market, FOR COMPANION ANIMAL VACCINES, BY TYPE, 2020–2027
      1. (USD MILLION) 92
    182. REPUBLIC OF KOREA: Veterinary (Animal) Vaccines Market, BY TECHNOLOGY, 2020–2027 (USD MILLION) 92
    183. REST OF ASIA-PACIFIC: Veterinary (Animal) Vaccines Market, BY TYPE, 2020–2027 (USD MILLION) 93
    184. REST OF ASIA-PACIFIC: Veterinary (Animal) Vaccines Market, FOR LIVESTOCK VACCINES, BY TYPE, 2020–2027
      1. (USD MILLION) 93
    185. REST OF ASIA-PACIFIC: Veterinary (Animal) Vaccines Market, FOR COMPANION ANIMAL VACCINES, BY TYPE, 2020–2027
      1. (USD MILLION) 94
    186. REST OF ASIA-PACIFIC: Veterinary (Animal) Vaccines Market, BY TECHNOLOGY, 2020–2027 (USD MILLION) 94
    187. MIDDLE EAST AND AFRICA: Veterinary (Animal) Vaccines Market, BY REGION, 2020–2027 (USD MILLION) 95
    188. MIDDLE EAST AND AFRICA: Veterinary (Animal) Vaccines Market, BY TYPE, 2020–2027 (USD MILLION) 96
    189. MIDDLE EAST AND AFRICA: Veterinary (Animal) Vaccines Market, FOR LIVESTOCK VACCINES, BY TYPE, 2020–2027
      1. (USD MILLION) 96
    190. MIDDLE EAST AND AFRICA: Veterinary (Animal) Vaccines Market, FOR COMPANION ANIMAL VACCINES, BY TYPE, 2020–2027 (USD MILLION) 97
    191. MIDDLE EAST AND AFRICA: Veterinary (Animal) Vaccines Market, BY TECHNOLOGY, 2020–2027 (USD MILLION) 97
    192. MIDDLE EAST: Veterinary (Animal) Vaccines Market, BY TYPE, 2020–2027 (USD MILLION) 98
    193. MIDDLE EAST: Veterinary (Animal) Vaccines Market, FOR LIVESTOCK VACCINES, BY TYPE, 2020–2027 (USD MILLION) 98
    194. MIDDLE EAST: Veterinary (Animal) Vaccines Market, FOR COMPANION ANIMAL VACCINES, BY TYPE, 2020–2027
      1. (USD MILLION) 99
    195. MIDDLE EAST: Veterinary (Animal) Vaccines Market, BY TECHNOLOGY, 2020–2027 (USD MILLION) 99
    196. AFRICA: Veterinary (Animal) Vaccines Market, BY TYPE, 2020–2027 (USD MILLION) 100
    197. AFRICA: Veterinary (Animal) Vaccines Market, FOR LIVESTOCK VACCINES, BY TYPE, 2020–2027 (USD MILLION) 100
    198. AFRICA: Veterinary (Animal) Vaccines Market, FOR COMPANION ANIMAL VACCINES, BY TYPE, 2020–2027 (USD MILLION) 101
    199. AFRICA: Veterinary (Animal) Vaccines Market, BY TECHNOLOGY, 2020–2027 (USD MILLION) 101
    200. List of Figures
    201. RESEARCH PROCESS 21
    202. TOP-DOWN & BOTTOM-UP APPROACH 24
    203. MARKET DYNAMICS: ANALYSIS OF THE GLOBAL Veterinary (Animal) Vaccines Market 26
    204. PORTER’S FIVE FORCES ANALYSIS: GLOBAL Veterinary (Animal) Vaccines Market 30
    205. SUPPLY CHAIN: GLOBAL Veterinary (Animal) Vaccines Market 32
    206. GLOBAL Veterinary (Animal) Vaccines Market, BY TYPE, 2020 (% SHARE) 35
    207. GLOBAL Veterinary (Animal) Vaccines Market, BY TYPE, 2020 & 2027 35
    208. GLOBAL Veterinary (Animal) Vaccines Market, BY TECHNOLOGY,2020 (% SHARE) 41
    209. GLOBAL Veterinary (Animal) Vaccines Market, BY TYPE, 2020 & 2027 42
    210. GLOBAL Veterinary (Animal) Vaccines Market, BY REGION, 2020 (% SHARE) 46
    211. GLOBAL Veterinary (Animal) Vaccines Market, BY REGION, 2020 & 2027 (USD MILLION) 46
    212. AMERICAS: Veterinary (Animal) Vaccines Market SHARE, BY REGION, 2020 (% SHARE) 48
    213. EUROPE: Veterinary (Animal) Vaccines Market SHARE, BY REGION, 2020 (% SHARE) 60
    214. ASIA-PACIFIC: Veterinary (Animal) Vaccines Market SHARE, BY COUNTRY, 2020 (% SHARE) 80
    215. MIDDLE EAST AND AFRICA: Veterinary (Animal) Vaccines Market SHARE, BY REGION, 2020 (% SHARE) 95
    216. GLOBAL Veterinary (Animal) Vaccines Market, MARKET SHARE ANALYSIS 2020 (%) 103
      1. "

    Veterinary (Animal) Vaccines Market Segmentation

    Market Segmentation Overview

    • Detailed segmentation data will be available in the full report
    • Comprehensive analysis by multiple parameters
    • Regional and country-level breakdowns
    • Market size forecasts by segment
    Infographic

    Free Sample Request

    Kindly complete the form below to receive a free sample of this Report

    Get Free Sample

    Customer Strories

    “I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

    Victoria Milne

    Founder
    Case Study
    Chemicals and Materials